ÌÇÐÄÊÓƵ

We take a deep dive into the stories behind the science

Renowned experts bring decades of experience to ÌÇÐÄÊÓƵ

Prominent global biotech investors including Canadian businessman Greg Bailey and British entrepreneur Jim Mellon have invested in ÌÇÐÄÊÓƵ, a new company developing a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

ÌÇÐÄÊÓƵ today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes.

ÌÇÐÄÊÓƵ’s Commercial Director Becky Verity explores the potential of digital therapeutics in mental health treatment.

We continue our look back at the heritage of the Beckley Foundation’s ground-breaking research programmes and the potential for ÌÇÐÄÊÓƵ, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnership. This latest instalment of the Science Explained series examines the link between the acute psychedelic experience and longer-term changes.

Q&A with ÌÇÐÄÊÓƵ CEO Cosmo Feilding Mellen

Dr. Laura Trespidi joins leadership team as Chief Development Officer

Partnership will capture behavioural and physiological signals and predictive biomarkers in ÌÇÐÄÊÓƵ’s upcoming Phase 2 clinical trialsNew digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey